Xilio Therapeutics, Inc. (XLO) income statement
XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3080% below fair value
$7.63+0.09 (+1.19%)
Close on Nov 18, 2026Market cap $44.12MP/E –Yield –
Xilio Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -48.9%
- Net margin
- -34.1%
- Return on equity, FY2025
- -132.5%
Financial strength
- Current ratio
- 4.25
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 397.8%
Valuation
- P/E ratio
- –
- Price to sales
- 0.69
- Price to book
- 0.61
- Dividend yield
- –
See a number that looks wrong?